Developing pharmaceutical treatments for peripheral artery disease

Bibliography

• BEEBE HG: Intermittent claudication: effective medical management of a common circulatory program. Am. J. Cardiol (2001) 87(Suppl.):14D–18D.
   Google Scholar
• COCCHERI S, PALARETTI G: The cardiovascular risk burden of intermittent claudication. Eur: Heart J. (2002) 4(Suppl. B):B46–B49.
   Google Scholar
• HIATT W: Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity. Eur. Heart J. (2002) 4(Suppl. B):B50–B84.
   Google Scholar
• SCHMIEDER FA, COMEROTA AJ: Intermittent claudication: magnitude of the program, patient evaluation and therapeutic strategies. Am. J. Cardiol. (2001) 87(Suppl.):3D–13D.
   Google Scholar
• HIRSCH AT, TREAT-JACOBSON D, LANDO HA, HATSUKAMI DK: The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc. Med (1997) 2:243–251.
   PubMedGoogle Scholar
• KANNEL WB, MC GEE DL: Update on some epidemiologic features of intermittent claudication: the Framingham Study. I Am. Ceriatr. Soc. (1985) 33:13–18.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, MC GEE DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA (1979) 241:2035–2038.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, D'AGOSTINO RB, WILSON PW et al.: Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am. Heart J. (1990) 120:672–676.
   Google Scholar
• FOWKES FG, HOUSLY E, RIEMERSMA RA et al.: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am. I Epidemiol (1992) 135:331–340.
   PubMed Web of Science ®Google Scholar
• BEACH KW, STRANDNESS DE: Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes (1980) 29:882–888.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effective of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• SMITH I, FRANKS PJ, GREENHALGH RM, POULTER NR, POWELL JT: The influence of smoking cessation and hypertriglyceridemia in the progression of peripheral arterial disease and the onset of critical ischemia. Eur. Endovasc. Surg. (1996) 11:402–408.
   PubMed Web of Science ®Google Scholar
• POMREHN P, DUNCAN B, WEISSFELD L et al: The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease: the lipids research clinics program prevalence study. Circulation (1986) 73(Suppl. I):1100–1107.
   Google Scholar
• DREXEL H, STEURERJ, MUNTWYLER J et al.: Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation (1996) 94 (Suppl. II): 11199–11205.
   Google Scholar
• VALENTINE JR, GRAYBURN PA, VEGA GL, GRUDY M: Lp(a) lipoprotein is an independent, discriminating risk factor for premature atherosclerosis among white men. Arch. Intern. Med (1994) 154:801–806.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• ELAMN MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA (2000) 284:1263–1270.
   PubMed Web of Science ®Google Scholar
• LENG GC, PRICE JF, JEPSON RG: Lipid-lower for lower limb atherosclerosis (Cochrane Review). Cochrane Database Sys" Rev (2000) 2:CD000123.
   Google Scholar
• DUFFIELD RGM, LEWIS B, MILLER NE, JAMESON CW, BRUNT JN, COLCHESTER AC: Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis; a randomised controlled trial. Lancet (1983) 2:639–642.
   PubMed Web of Science ®Google Scholar
• SALONEN R, NYYSONEN K, PORKKALA E et al.: KAPS: a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation (1995) 92:1758–1764.
   PubMed Web of Science ®Google Scholar
• Executive summary of the Third Report ofthe National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• MURABITO JM, D'AGOSTINO RB, SILBERSHATZ H, WILSON WF: Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation (1997) 96:44–49.
   PubMedGoogle Scholar
• SOLOMON SA, RAMSAY LE, YEO WW, PARNELL L, MORRIS-JONES W: I3-blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. Br. Med. J. (1991) 303:1100–1104.
   PubMed Web of Science ®Google Scholar
• RADACK K, DECK C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch. Intern. Med. (1991) 151:1769–1779.
   PubMed Web of Science ®Google Scholar
• POLDERMANS D, BOERSMA E, BAX JJet al.: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl. J. Med. (1999) 341:1789–1794.
   Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng" I Med. (2000) 342:145–153.
   Google Scholar
• TASC: Management of peripheral arterialdisease. Transatlantic Intersociety Consensus. I Vase. Surg (2000) 31:S92–S93.
   Google Scholar
• GRAHAM IM, DALY LE, REFSUM HM et al.: Plasma homocysteine as a risk for vascular disease: the European Concerted Action Project. JA/VIA (1997) 227:1775–1781.
   Google Scholar
• CLARKE R, DALY L, ROBINSON K et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl. J. Med. (1991) 324:1149–1155.
   PubMed Web of Science ®Google Scholar
• BOUSHEY CJ, BERESFORD SA, OMERIN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. N Engl. J. Med (1991) 324:1149–1155.
   PubMedGoogle Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ(2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• BALSANO F, VIOLI F, ADEP GROUP: Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation (1993) 87:1563–1569.
   PubMed Web of Science ®Google Scholar
• JANZON L, BERGQVIST D, BOBERG J et al.: Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicenter Study. J. Intern. Med. (1990) 227:301–308.
   PubMed Web of Science ®Google Scholar
• BALSANO F, COCCHERI S, LIBRETTI A et al.: Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. I. Lab. Clin. Med (1989) 114:84–91.
   PubMedGoogle Scholar
• BERGQVIST D, ALMGREN B, DICKINSON JP: Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur.j Vasc. Endovasc. Sing. (1995) 10:69–76.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, WEINBERG PD, ROZENBERG-BEN-DROR K, YARNOLD PR, KWAAN HC, GREEN D: Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann. Intern. Med. (1998) 128:541–544.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, SUDLOW CL, DUNBABIN DW: Thienopyridine derivates (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst. Rev (2000) 2:CD001246.
   Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, CONNORS JM, CARWILE JM et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl. J. Med (2000) 342:1773–1777.
   PubMed Web of Science ®Google Scholar
• Prevention of atherosclerotic complications:controlled trial of ketanserin. BMI(1989) 298:424–430.
   PubMed Web of Science ®Google Scholar
• Randomized placebo-controlled, double blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure: PACK Claudication Substudy. Circulation (1989) 89:1544–1548.
   Google Scholar
• MONEY SR, HERD JA, ISAACSOHN JL et al.: Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease...! Vase. Sing. (1998) 27:267–274.
   PubMed Web of Science ®Google Scholar
• DAWSON DL, CUTLER BS, MESSNER MH, STRANDNESS DEJ: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter randomised, prospective, double-blind trial. Circulation (1998) 98:678–686.
   PubMed Web of Science ®Google Scholar
• BEEBE HG, DAWSON DL, CUTLER BS et al.: A new pharmacological treatment for intermittent claudication: results of a randomised, multicenter trial. Arch. Intern. Med. (1999) 159:2041–2050.
   PubMed Web of Science ®Google Scholar
• DAWSON DL, CUTLER BS, HIATT WR et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med (2000) 109:523–530.
   PubMed Web of Science ®Google Scholar
• STRANDNESS DE Jr, DALMAN RL, PANIAN S et al.: Effect of cilostazol in patients with intermittent claudication: a randomised, double-blind, placebo-controlled study. Vasc. Endovasc. Surg. (2002) 36:83–91.
   PubMedGoogle Scholar
• HIATT WR: Medical treatment of peripheral arterial disease and claudication. N Engl. J. Med. (2001) 344:1608–1621.
   PubMed Web of Science ®Google Scholar
• SAMKASKA CP, WINFIELD EA: Pentoxifylline. J. Am. Acad. Dermatol (1994) 30:603–621.
   PubMed Web of Science ®Google Scholar
• PORTER JM, CUTLER BS, LEE BY et al:Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. (1982) 104:66–72.
   PubMed Web of Science ®Google Scholar
• LIND GARDE F, JELNES R, BJORKMANH et al: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation (1989) 80:1549–1556.
   PubMed Web of Science ®Google Scholar
• GIROLAMI B, BERNARDI E, PRINS MH et al.: Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or naftidrofuryl: a meta-analysis. Arch. Intern. Med. (1999) 159:337–345.
   PubMed Web of Science ®Google Scholar
• HOOD SC, MOHER D, BARBER GG: Management of intermittent claudication with pentoxifylline: meta-analysis of randomised controlled trials. CMAJ(1996) 155:1053–1059.
   PubMed Web of Science ®Google Scholar
• ERNST E: Pentoxifylline for intermittentclaudication: a critical review. Angiology (1994) 45:339–345.
   PubMed Web of Science ®Google Scholar
• RADACK K, WYDERSKI RJ: Conservative management of intermittent claudication. Ann. Intern. Med (1990) 113:135–146.
   PubMed Web of Science ®Google Scholar
• LEHERT P, COMTE S, GAMAND S, BROWN TM: Naftidrofuryl in intermittent claudication: a retrospective analysis. J. Cardiovasc. Pharmacol (1994) 23\(Suppl. 3):S48–S52.
   Google Scholar
• MOODY AP, AL-KHAFFAF HS, LEHERT P, HARRIS PL, CHARLESWORTH D: An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.j Cardiovasc. Pharmacol (1994) 23\(Suppl. 3):544–547.
   Google Scholar
• TRUBESTEIN G, BOKME H, HEIDRICH H et al.: Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study. Angiology (1994) 35:701–708.
   Google Scholar
• ADHOUTE G, ANDREASSIAN B, BOCCALON H et al.: Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol (1990) 16\(Suppl. 3):S75–S80.
   Google Scholar
• ADHOUTE G, BACOURT F, BARRAL M et al: Naftidrofuryl in chronic arterial disease: results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology(1986) 37:160–169.
   PubMed Web of Science ®Google Scholar
• KRIESSMANN A, NETS A: Demonstration of the clinical effectiveness of naftidrofuryl in intermittent claudication. VASA (1988) 24:27–32.
   PubMedGoogle Scholar
• TRUBESTEIN G, BALZER K, BISLER H: Buflomedil in arterial occlusive disease: results of a controlled multicentre study. Angiology (1984) 35:500–505.
   PubMed Web of Science ®Google Scholar
• DIAMANTOPOULOS EJ, GRIGORIADOU M, IFANTI G, RAPTY SA: Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. hat. Angiol (2001) 20:337–344.
   Web of Science ®Google Scholar
• BREVETTI G, PERNA S, SABBA C, MARTONE VD, CONDORELLI M: Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J. Am. Coll Cardiol (1995) 26:1411–1416.
   PubMed Web of Science ®Google Scholar
• BREVETTI G, DIEHM C, LAMBERT D: European multicenter study on propionyl- L-carnitine in intermittent claudication.Am. Coll Cardiol (1999) 34:1618–1924.
   Google Scholar
• BREVETTI G, PERNA S, SABBA C et al:Superiority of L-propionylcarnitine versus L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Laic Heart .1. (1992) 13:251–255.
   PubMed Web of Science ®Google Scholar
• BALSANO F, COCCHERI S, LIBRETTI A et al: Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. j. Lab. Clin. Med (1989) 114:84–91.
   PubMedGoogle Scholar
• ARCAN JC, BLANCHARD J, BORSSEL JP, DESTORSE JM, PANNAH E: Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology (1988) 39:802–811.
   PubMed Web of Science ®Google Scholar
• BELCH JJF, BELL PRF, CREISSEN D et al.: Randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin El prodrug in patients with intermittent claudication. Circulation (1997) 95:2298–2302.
   PubMed Web of Science ®Google Scholar
• LIEVRE M, AZOULY S, LION L, MORAND S, GIRRE JP, BOISSEL JP: A dose effect study of beraprost sodium in intermittent claudication. Cardiovasc. Pharmacol. (1996) 27:788–793.
   PubMed Web of Science ®Google Scholar
• LIEVRE M, MORAND S, BESSE B, FIESSINGERJN, BOISSEL JP: Oral beraprost sodium, a prostaglandin 1(2) analogue, for intermittent claudication: a double-blind, randomised, multicenter controlled trial. Circulation (2000) 102:426–431.
   PubMed Web of Science ®Google Scholar
• HIRSCH AT, HIATT WR, CRIQUI MH et al.: PARTNERS: A National Survey of Peripheral Arterial Disease (PAD) Symptoms and Treatment Intensity.' Am. Cardiol. (2001) 37(2, Suppl. A):226A.
   Google Scholar